For patients with metabolic dysfunction–associated steatohepatitis and liver fibrosis, survodutide, a dual agonist of the glucagon and GLP-1 receptors, may confer clinical advantages. Research findings are summarized in a new Quick Take video. nej.md/3SmZ2im

In a new trial, researchers evaluated the efficacy and safety of multiple subcutaneous doses of survodutide, a dual agonist of the glucagon receptor and GLP-1 receptor, in participants with MASH and liver fibrosis. Full trial results: nej.md/4bBXQPF

As many of you know, nurturing the next-gen of HEP is dear to my heart. I want to congratulate our own Madison Nguyen, a rising third year resident at #VCU SOM, for her selection as an @AASLD Emerging #Liver Scholar for 2024. bit.ly/3SuFxED #livertwitter

Appreciate the coverage of Arun J. Sanyal work on survodutide by @AGA_GHIN.

.Arun J. Sanyal will discuss MASH and its consequences at the Economist Impact ISGlobal event.

Congratulations, Obi Aseem!

Looking forward to the event and the opportunity to connect with policymakers about liver disease and its tremendous global impact.

Happy to see everyone and participate in INASL 2024!

"With the urgent unmet need of patients with +MASH, we hope that AIM-MASH can aid pathologists in the clinical trial setting.” --the paper's co-authors include director Arun J. Sanyal.

What an honour to have the world-renowned expert in #cirrhosis Jasmohan Bajaj to deliver this named lecture on #oral #gut #liver #axis in IDDF - International Digestive Disease Forum 2024! CUHK Medicine CUHK Gastroenterology & Hepatology Vincent Wong Terry Cheuk-Fung Yip Jimmy Che-To Lai

Missed our #webinar this week on #MASH and its effects on people living with #HIV? Watch the recording of the webinar using the following link! ➡️ bit.ly/3yGGBi1 #livertwitter #MASH #HIV

We are busy preparing for the first United Nations General Assembly MASH side-event, 23 Sept 2024 - in NYC. We need a whole-of-society effort to end this public health threat. For ex food inequity + insecurity are MASLD and MASH risk factors: nature.com/articles/s4157… #LiverTwitter

Want to be part of the latest clinical breakthroughs in MASLD? Paris MASH 2024 is where it happens. Secure your seat today and don’t miss the debate on Met-ALD classification! #MASH2024 #ClinicalInnovation #RegisterNow paris-mash.org

Looking forward to participating in this Economist Impact via ISGlobal presentation.

Ready to shape the future of MASLD treatment? Paris MASH 2024 is your gateway to the latest in clinical trials and research strategies. Spots are filling fast—register now! #MASH2024 #ClinicalTrials #RegisterToday paris-mash.org

ICYMI! Participate in the first ALF #Liver Life Walk here in Richmond on Sat., Oct. 12. Donate or sign up to walk with team “UnStoppable VCU Liver” at liverlifewalk.org/virginia/ #LiverLifeWalk #UnStoppableVCULiver #LiverTwitter VCU Stravitz-Sanyal Institute for Liver Disease American Liver Foundation National

Just one day to go! Finalize your plans and register now to be part of the Paris MASH Meeting 2024. It’s not too late to join us! #MASH2024 #MASLD #LastChance paris-mash.org/registration

Happy to share our narrative review of the natural history of MASLD in The Lancet Gastroenterology & Hepatology Link: thelancet.com/journals/langa… Ying Shang Patrik Nasr Hannes Hegmar #LiverTwitter Karolinska Institutet

In The Lancet: GLP-1 receptor agonists, such as semaglutide, could curb both health & economic effects of obesity. In a Viewpoint, authors analyse GLP-1 receptor agonist coverage policies in 13 high-income countries to draw lessons for policy development: bit.ly/47gX2yz

Some very important research by our Jasmohan Bajaj that should give you pause to consider how we treat these patients.